Attached files
| file | filename |
|---|---|
| EX-3.3 - Cellectar Biosciences, Inc. | v227496_ex3-3.htm |
| EX-10.33 - Cellectar Biosciences, Inc. | v227496_ex10-33.htm |
| EX-10.34 - Cellectar Biosciences, Inc. | v227496_ex10-34.htm |
| EX-10.32 - Cellectar Biosciences, Inc. | v227496_ex10-32.htm |
| EX-10.31 - Cellectar Biosciences, Inc. | v227496_ex10-31.htm |
| S-1 - Cellectar Biosciences, Inc. | v227496_s1.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated June 14, 2011, with respect to the financial statements of Novelos Therapeutics, Inc. contained in the Registration Statement and Prospectus. We consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption "Experts."
/s/ GRANT THORNTON LLP
Chicago, Illinois
June 30, 2011